Section: New Results

Analysis of results from Clinical trials and cohorts in Ebola

• Rechtien A, Richert L, Lorenzo H, Martrus G, Hejblum B, Dahlke C, Kasonta R, Zinser M, Stubbe H, Matschl U, Lohse A, Krähling V, Eickmann M, Becker S; VEBCON Consortium, Thiébaut R, Altfeld M, Addo MM. Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. Cell Report. 2017;20:2251-2261. [30]

  In this work, we have analyzed high-dimensional gene expression and cell characterization data. We showed the predictive capacity of the innate immune response to the Ebola vaccine to define the antibody response established beyond one month. This is a successful application of integrative analyses tools on high dimensional immunogenicity data from an Ebola vaccine trial with identification of early correlates of later antibody responses.